Add-on Peginterferon Alfa-2a significantly reduces HBsAg levels in chronic hepatitis B, HBeAg-negative, genotype D patients fully suppressed on nucleot(s)ide analogues treatment: HERMES Study Interim Analysis

被引：0
|
作者：
Lampertico, Pietro [1 ]
Brunetto, Maurizia R. [2 ,3 ]
Craxi, Antonio [4 ]
Gaeta, Giovanni B. [5 ]
Rizzetto, Mario [6 ]
Palmieri, Giulio [7 ]
Colombo, Massimo [1 ]
机构：
[1] Univ Milan, Div Gastroenterol & Hepatol, Osped Maggiore Policlin, Milan, Italy
[2] Univ Hosp Pisa, Reference Ctr Chron Liver Desease, Liver Unit, Pisa, Italy
[3] Univ Hosp Pisa, HCC Tuscany Reg, Pisa, Italy
[4] Univ Palermo, Di Bi MIS, Palermo, Italy
[5] Univ Naples 2, Dept Internal Med, Sect Infect Desease, Naples, Italy
[6] Univ Turin, Dept Gastroenterol, Turin, Italy
[7] Roche SpA, Monza, Italy
来源：
HEPATOLOGY | 2014年 / 60卷 / 06期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
LB-31
引用
收藏
页码：1285A / 1286A
页数：2
相关论文
共 50 条
  • [41] Early reduction of serum HBsAg Levels in HBeAg-negative chronic hepatitis B patients achieving sustained virological response after peginterferon α-2a± ribavirin treatment
    Rijckborst, V.
    ter Borg, M. J.
    Akarca, U. S.
    Grima, P.
    Flisiak, R.
    Zouboulis, I. Vafiadis
    Tripi, S.
    van Doornum, G. J. J.
    Verhey, E.
    van Vuuren, A. J.
    Hansen, B. E.
    Janssen, H. L. A.
    EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2009, 21 (03) : A65 - A65
  • [42] A prospective study of nucleot(s)ide analog discontinuation in non-cirrhotic patients with HBeAg-negative chronic hepatitis B: Interim analysis identifies different viral kinetics after stopping tenofovir versus entecavir
    Hall, S.
    Burns, G.
    Anagnostou, D.
    Vogrin, S.
    Levy, M.
    Sievert, W.
    Lubel, J.
    Nicoll, A.
    Strasser, S.
    Desmond, P.
    Ngu, M.
    Angus, P.
    Meredith, C.
    Revill, P.
    Jackson, K.
    Bowden, S.
    Locarnini, S.
    Visvanathan, K.
    Thompson, A.
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 : 76 - 77
  • [43] A prospective study of nucleot(s)ide analogue discontinuation in non-cirrhotic HBeAg-negative chronic hepatitis B patients: interimanalysis at week 48 demonstrates profound reductions of HBsAg associated with ALT flare
    Hall, Samuel
    Burns, Gareth
    Levy, Miriam
    Lubel, John
    Nicoll, Amanda
    Matthews, Gail
    Desmond, Paul
    Sievert, William
    Bowden, Scott
    Locarnini, Stephen
    Holmes, Jacinta
    JOURNAL OF HEPATOLOGY, 2020, 73 : S69 - S70
  • [44] HBSAG LEVELS DECLINE > 10% DURING 48 WEEKS OF PEGINTERFERON ALFA-2A [40KD] (PEGASYS) TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE CHRONIC HEPATITS B (CHB) FAVORS END OF TREATMENT RESPONSE: PRELIMINARY ANALYSIS OF THE PERSEAS COHORT
    Goulis, Loannis
    Akriviadis, Evangelos
    Karatapanis, Stylianos
    Deutsch, Melanie
    Dalekos, George N.
    Raptopoulou-Gigi, Maria P.
    Drakoulis, Christos
    Mimidis, Konstantinos
    Germanidis, Georgios
    Nikolopoulou, Vasiliki
    Chounta, Athina
    Bakalos, George
    Papatheodoridis, George V.
    HEPATOLOGY, 2011, 54 : 1019A - 1020A
  • [45] Durability of response to peginterferon alfa-2a (40 KD) (PEGASYS®) treatment in Asian patients with HBeAg-negative chronic hepatitis B:: 12 month follow-up data from a large randomised study
    Lau, George
    Marcellin, Patrick
    Piratvisuth, Teerha
    Jin, Rui
    Lu, Zhi-Meng
    Lai, Ming-Yang
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2006, 21 : A33 - A33
  • [46] A FINITE COURSE OF PEGINTERFERON ALFA-2A RESULTS IN INACTIVE CHRONIC HEPATITIS B AND HBSAG CLEARANCE 5 YEARS POST-TREATMENT IN PATIENTS WITH HBEAG-NEGATIVE DISEASE: BASELINE CHARACTERISTICS AND PREDICTIVE FACTORS OF LONG-TERM RESPONSE
    Marcellin, Patrick
    Piratvisuth, Teerha
    Brunetto, Maurizia R.
    Bonino, Ferruccio
    Farci, Patrizia
    Yurdaydin, Cihan
    Gurel, Selim
    Kapprell, Hans-Peter
    Messinger, Diethelm
    Batrla, Richard
    HEPATOLOGY, 2009, 50 (04) : 487A - 487A
  • [47] CHANGES IN HBSAG LEVELS AMONG PATIENTS WITH CHRONIC HEPATITIS B TREATED WITH PEGINTERFERON ALFA-2A [40KD] ENROLLED IN THE S-COLLATE COHORT STUDY
    Marcellin, Patrick
    Xie, Yao
    Chen, Xiao P.
    Lou, GuoQiang
    Chen, Yong-Ping
    Rothe, Vivien
    Regep, Loredana
    Martins, Eduardo B.
    Jia, Jidong
    Wei, Lai
    HEPATOLOGY, 2010, 52 (04) : 523A - 523A
  • [48] CHANGES IN HBEAG LEVELS AMONG PATIENTS WITH HBEAG-POSITIVE CHRONIC HEPATITIS B TREATED WITH PEGINTERFERON ALFA-2A [40KD] ENROLLED IN THE S-COLLATE COHORT STUDY
    Lou, GuoQiang
    Marcellin, Patrick
    Xie, Yao
    Chen, Xiao P.
    Chen, Yong-Ping
    Rothe, Vivien
    Regep, Loredana
    Martins, Eduardo B.
    Jia, Jidong
    Wei, Lai
    HEPATOLOGY, 2010, 52 (04) : 537A - 537A
  • [49] FINAL RESULTS OF THE HBV-STOP STUDY - LOW BASELINE HBsAg LEVELS PREDICT DISEASE REMISSION AND HBsAg LOSS AFTER STOPPING NUCLEOT(S)IDE ANALOGUES IN CHRONIC HEPATITIS B E-ANTIGEN NEGATIVE PATIENTS
    Hall, Samuel
    Burns, Gareth
    Anagnostou, Despina
    Vogrin, Sara
    Sundararajan, Vijaya
    Ratnam, Dilip T.
    Levy, Miriam T.
    Lubel, John S.
    Nicoll, Amanda J.
    Strasser, Simone I.
    Sievert, William
    Desmond, Paul V.
    Ngu, Meng Chong
    Angus, Peter W.
    Maree, Sinclair
    Meredith, Christopher
    Matthews, Gail
    Revill, Peter
    Jackson, Kathy
    Bonanzinga, Sara
    Canchola, Jesse
    Kuchta, Alison
    Torres, Jason
    Bowden, Scott
    Locarnini, Stephen
    Visvanathan, Kumar
    Thompson, Alexander
    HEPATOLOGY, 2021, 74 : 482A - 483A
  • [50] EFFICACY AND SAFETY OF PEGINTERFERON alfa-2a (40KD) IN HBeAg-POSITIVE CHRONIC HEPATITIS B PATIENTS PARTICIPATING IN A RESPONSE-GUIDED THERAPY STUDY: AN INTERIM ANALYSIS AT WEEK 72
    Hou, J.
    Ma, H.
    Sun, J.
    Xie, Q.
    Xie, Y.
    Sun, Y.
    Wang, H.
    Shi, G.
    Wan, M.
    Niu, J.
    Ning, Q.
    Yu, Y.
    Zhao, Y.
    JOURNAL OF HEPATOLOGY, 2013, 58 : S303 - S304
12345